Biogen to Acquire Vigil Neuroscience for $7.50/share + CVR
| Field | Detail |
|---|---|
| Company | Vigil Neuroscience, Inc. |
| Form Type | 8-K |
| Filed Date | Jul 17, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, biotech, merger, cvr
Related Tickers: BIIB
TL;DR
Biogen buying Vigil for $7.50 cash + $1.25 CVR. Deal expected H2 2025.
AI Summary
Vigil Neuroscience, Inc. announced on July 16, 2025, that it has entered into a definitive agreement to be acquired by Biogen Inc. for $7.50 per share in cash, plus a potential CVR of $1.25 per share. This transaction is expected to close in the second half of 2025, subject to customary closing conditions.
Why It Matters
This acquisition by a major player like Biogen could significantly impact the development of Vigil's lead product candidate, potentially accelerating its path to market and offering a substantial return to Vigil shareholders.
Risk Assessment
Risk Level: medium — The deal is subject to closing conditions and regulatory approvals, and the CVR payout depends on future clinical trial success.
Key Numbers
- $7.50 — Acquisition Price per Share (Cash) (The upfront cash payment Vigil shareholders will receive.)
- $1.25 — Contingent Value Right (CVR) per Share (Potential additional payment tied to future milestones.)
Key Players & Entities
- Vigil Neuroscience, Inc. (company) — Company filing the report and being acquired
- Biogen Inc. (company) — Acquiring company
- $7.50 (dollar_amount) — Cash purchase price per share
- $1.25 (dollar_amount) — Contingent Value Right (CVR) per share
- July 16, 2025 (date) — Date of the definitive agreement
- second half of 2025 (date) — Expected closing period for the acquisition
FAQ
What is the total potential value per share for Vigil shareholders?
The total potential value per share is $8.75, consisting of $7.50 in cash plus a $1.25 CVR.
Who is acquiring Vigil Neuroscience?
Biogen Inc. is acquiring Vigil Neuroscience.
When is the acquisition expected to close?
The acquisition is expected to close in the second half of 2025.
What is the primary condition for the CVR payout?
The filing implies the CVR payout is contingent on future clinical trial success, though specific milestones are not detailed in this excerpt.
What is Vigil Neuroscience's primary business?
Vigil Neuroscience is focused on developing treatments for neurodegenerative diseases, as indicated by its SIC code for Biological Products.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 17, 2025 regarding Vigil Neuroscience, Inc..